A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

Percent Change from Baseline in Body Weight

Time frame: Baseline up to 72 weeks

Change from Baseline in HbA1c at Week 72

Time frame: Baseline, Week 72

Change from Baseline in Fasting Glucose

Time frame: Baseline up to 72 weeks

Percentage of Participants Achieving HbA1c of <7.0%

Time frame: Baseline up to 72 weeks

Percentage of Participants Achieving Weight Reduction of ≥5%

Time frame: Baseline up to 72 weeks

Change from Baseline in Waist Circumference

Time frame: Baseline up to 72 weeks

Change from Baseline in Body Mass Index (BMI)

Time frame: Baseline, Week 72

Change from Baseline in Systolic Blood Pressure (SBP)

Time frame: Baseline up to 72 weeks

Percent Change from Baseline in Triglycerides

Time frame: Baseline up to 72 weeks

Change from Baseline in EQ-5D-5L

Time frame: Baseline, Week 72

Pharmacokinetics (PK): Steady State Area Under the Concentration Time Curve (AUC-ss) of Orforglipron